Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 7:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Carcinoma, Transitional Cell Clear all
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Carcinoma of Urinary Tract, Urethral Carcinoma, Carcinoma of Ureter, Carcinoma of Renal Pelvis
Interventions
Docetaxel, Ramucirumab DP, Icrucumab
Drug · Biological
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
26
States / cities
Los Angeles, California • Sacramento, California • San Francisco, California + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2019 · Synced May 21, 2026, 7:20 PM EDT
Active, not recruiting Phase 3 Interventional Results available
View directory record Official record
Conditions
Various Advanced Cancer
Interventions
Nivolumab, Placebo
Biological · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
709 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
33
States / cities
Anchorage, Alaska • Tucson, Arizona • Clovis, California + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced May 21, 2026, 7:20 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Urothelial Carcinoma
Interventions
Atezolizumab, Carboplatin, Gemcitabine, Placebo, Cisplatin
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
1,213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
18
States / cities
Rogers, Arkansas • San Luis Obispo, California • New Haven, Connecticut + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2025 · Synced May 21, 2026, 7:20 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Carcinoma, Transitional Cell, Bladder Cancer, Bladder Neoplasm
Interventions
Pralatrexate Injection, Vitamin B12, Folic Acid
Drug · Dietary Supplement
Lead sponsor
Acrotech Biopharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
4
States / cities
Tucson, Arizona • Atlanta, Georgia • Rochester, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced May 21, 2026, 7:20 PM EDT
Active, not recruiting Phase 1 Interventional
View directory record Official record
Conditions
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Locally Advanced Gastric Adenocarcinoma, Locally Advanced Gastroesophageal Junction Adenocarcinoma, Locally Advanced Urothelial Carcinoma, Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Urothelial Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Refractory Lung Non-Small Cell Carcinoma, Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage IV Lung Cancer AJCC v8, Unresectable Malignant Solid Neoplasm, Unresectable Melanoma
Interventions
Pembrolizumab, Sonidegib
Biological · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced May 21, 2026, 7:20 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
Interventions
carboplatin, gemcitabine, paclitaxel, surgery
Drug · Procedure
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
128
States / cities
Anchorage, Alaska • Glendale, Arizona • Mesa, Arizona + 89 more
Source: ClinicalTrials.gov public record
Updated May 26, 2013 · Synced May 21, 2026, 7:20 PM EDT
Not yet recruiting Phase 2 Interventional
View directory record Official record
Conditions
Bladder Urothelial Carcinoma
Interventions
Stereotactic body radiotherapy, Cemiplimab, Cemiplimab and Fianlimab, Radical cystectomy
Radiation · Drug · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced May 21, 2026, 7:20 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Amyloidosis, Basal Cell Carcinoma, Biliary Tract Carcinoma, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Fallopian Tube Carcinoma, Gastroesophageal Junction Carcinoma, Glioblastoma, Head and Neck Carcinoma, Hematopoietic and Lymphatic System Neoplasm, Hepatocellular Carcinoma, Hodgkin Lymphoma, Lung Carcinoma, Malignant Solid Neoplasm, Mantle Cell Lymphoma, Melanoma, Merkel Cell Carcinoma, Multiple Myeloma, Myelodysplastic Syndrome, Ovarian Carcinoma, Pancreatic Carcinoma, Primary Peritoneal Carcinoma, Prostate Carcinoma, Renal Cell Carcinoma, Squamous Cell Carcinoma, Urothelial Carcinoma
Interventions
Cancer Therapeutic Procedure, Questionnaire Administration
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced May 21, 2026, 7:20 PM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Cervical Squamous Cell Carcinoma, Squamous Non-small-cell Lung Cancer, Colorectal Cancer, Intrahepatic Cholangiocarcinoma, Urothelial Carcinoma
Interventions
ALE.P03
Drug
Lead sponsor
Alentis Therapeutics AG
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
8
States / cities
Phoenix, Arizona • Los Angeles, California • New Haven, Connecticut + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced May 21, 2026, 7:20 PM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Infiltrating Bladder Urothelial Carcinoma, Stage II Bladder Urothelial Carcinoma, Stage III Bladder Urothelial Carcinoma
Interventions
Gemcitabine Hydrochloride, Cisplatin, Pegfilgrastim, Conventional Surgery, Radical Cystectomy, Chemoradiotherapy
Drug · Biological · Procedure + 1 more
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
424
States / cities
Fairbanks, Alaska • Goodyear, Arizona • Phoenix, Arizona + 293 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced May 21, 2026, 7:20 PM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Locally Advanced or Metastatic Urothelial Carcinoma
Interventions
Avelumab, Sacituzumab Govitecan, M6223, NKTR-255
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
8
States / cities
Coeur d'Alene, Idaho • Kansas City, Kansas • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced May 21, 2026, 7:20 PM EDT
Terminated Phase 2 Interventional
View directory record Official record
Conditions
Cervical Cancer, Colorectal Cancer, Esophageal Cancer, Gastric Cancer, Glioblastoma Multiforme, Cholangiocarcinoma, Hepatocellular Carcinoma, Head and Neck Squamous Cell Carcinoma, Nasopharyngeal Carcinoma, Non Small Cell Lung Cancer, Small Cell Lung Cancer, Epithelial Ovarian Cancer, Pancreatic Ductal Adenocarcinoma, Soft Tissue Sarcoma, Gastric Adenocarcinoma, Malignant Mesothelioma (MM), Von Hippel Lindau, Bladder Cancer, Bladder Urothelial Carcinoma
Interventions
89Zr-girentuximab for PET/CT imaging of CAIX positive tumors
Diagnostic Test
Lead sponsor
Telix Pharmaceuticals (Innovations) Pty Ltd
Industry
Eligibility
18 Years to 95 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
10
States / cities
Los Angeles, California • Miami, Florida • Boston, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2025 · Synced May 21, 2026, 7:20 PM EDT
Withdrawn Not applicable Interventional
View directory record Official record
Conditions
Infiltrating Bladder Urothelial Carcinoma, Stage II Bladder Urothelial Carcinoma, Stage III Bladder Urothelial Carcinoma, Stage IV Bladder Urothelial Carcinoma
Interventions
Cisplatin, Gemcitabine Hydrochloride, Radical Cystectomy, Tumor Cell-Derived Vaccine Therapy
Drug · Procedure · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 16, 2017 · Synced May 21, 2026, 7:20 PM EDT
Terminated Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Ovarian Cancer, Triple-negative Breast Cancer, Urothelial Carcinoma, Solid Tumor
Interventions
Rucaparib, Lucitanib, Sacituzumab govitecan
Drug
Lead sponsor
pharmaand GmbH
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
3
States / cities
Boston, Massachusetts • Nashville, Tennessee • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 15, 2024 · Synced May 21, 2026, 7:20 PM EDT
Recruiting Not applicable Interventional
View directory record Official record
Conditions
Upper Tract Urothelial Cancer
Interventions
Bladder CARE™
Diagnostic Test
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 11, 2025 · Synced May 21, 2026, 7:20 PM EDT
Withdrawn Phase 1 Interventional
View directory record Official record
Conditions
Stage 0 Bladder Urothelial Carcinoma AJCC v6 and v7, Stage 0a Bladder Urothelial Carcinoma AJCC v6 and v7, Stage 0is Bladder Urothelial Carcinoma AJCC v6 and v7, Stage I Bladder Urothelial Carcinoma AJCC v6 and v7
Interventions
Laboratory Biomarker Analysis, Talimogene Laherparepvec
Other · Biological
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 27, 2020 · Synced May 21, 2026, 7:20 PM EDT
Suspended Phase 1 Interventional
View directory record Official record
Conditions
Metastatic Malignant Neoplasm
Interventions
NPX267
Drug
Lead sponsor
NextPoint Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
7
States / cities
Baltimore, Maryland • Boston, Massachusetts • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2025 · Synced May 21, 2026, 7:20 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Advanced Biliary Tract Carcinoma, Advanced Colorectal Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Advanced Lung Adenocarcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma, Advanced Pancreatic Carcinoma, Advanced Urothelial Carcinoma, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Metastatic Biliary Tract Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Lung Adenocarcinoma, Metastatic Ovarian Carcinoma, Metastatic Pancreatic Carcinoma, Metastatic Urothelial Carcinoma, Refractory Biliary Tract Carcinoma, Refractory Colorectal Carcinoma, Refractory Gastroesophageal Junction Adenocarcinoma, Refractory Lung Adenocarcinoma, Refractory Ovarian Carcinoma, Refractory Pancreatic Carcinoma, Refractory Urothelial Carcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Devimistat, Fluorouracil, Gemcitabine Hydrochloride, Hydroxychloroquine, Magnetic Resonance Imaging
Procedure · Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 9, 2023 · Synced May 21, 2026, 7:20 PM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Colorectal Cancer, Gastroesophageal Adenocarcinoma, Urothelial Carcinoma, Pancreatic Ductal Adenocarcinoma
Interventions
Blood collection for research (next-generation sequencing [NGS]), Blood collection for research (HLA typing)
Procedure
Lead sponsor
Gritstone bio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
5
States / cities
Chicago, Illinois • New York, New York • Columbus, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2020 · Synced May 21, 2026, 7:20 PM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Melanoma, Solid Tumor, CRAF Gene Amplification, RAF1 Gene Amplification, BRAF Gene Fusion, BRAF Fusion, CRAF Gene Fusion, CRAF Fusion, RAF1 Gene Fusion, RAF1 Fusion, Thyroid Cancer, Papillary, Spitzoid Melanoma, Pilocytic Astrocytoma, Pilocytic Astrocytoma, Adult, Non Small Cell Lung Cancer, Non-Small Cell Adenocarcinoma, Colorectal Cancer, Pancreatic Acinar Carcinoma, Spitzoid Malignant Melanoma, Bladder Cancer, Bladder Urothelial Carcinoma, MAP Kinase Family Gene Mutation, RAF Mutation
Interventions
Tovorafenib
Drug
Lead sponsor
Day One Biopharmaceuticals, Inc.
Industry
Eligibility
12 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
8
States / cities
Los Angeles, California • Newport Beach, California • Aurora, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced May 21, 2026, 7:20 PM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Non-squamous Non-small-cell Lung Cancer, Urothelial Carcinoma, Malignant Mesothelioma
Interventions
Cabozantinib, Pemetrexed
Drug
Lead sponsor
Augusta University
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 13, 2022 · Synced May 21, 2026, 7:20 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Bladder Neoplasms, Carcinoma, Transitional Cell
Interventions
suramin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced May 21, 2026, 7:20 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma
Interventions
Sacituzumab tirumotecan, Enfortumab Vedotin, Pembrolizumab, Supportive care measures
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
8
States / cities
San Francisco, California • Chicago, Illinois • Indianapolis, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced May 21, 2026, 7:20 PM EDT
Active, not recruiting Phase 3 Interventional
View directory record Official record
Conditions
Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder
Interventions
UGN-103
Drug
Lead sponsor
UroGen Pharma Ltd.
Industry
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
17
States / cities
Loma Linda, California • San Diego, California • Washington D.C., District of Columbia + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced May 21, 2026, 7:20 PM EDT